<DOC>
	<DOC>NCT02536664</DOC>
	<brief_summary>It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in participants with previously untreated, relapsed or refractory cluster of differentiation 20 (CD20)-positive follicular lymphoma (FL) in clinical practice.</brief_summary>
	<brief_title>Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age over 18 years Previously untreated, relapsed or refractory CD 20positive FL Responding to rituximab containing induction therapy (complete response [CR] or partial response [PR]) To receive rituximab maintenance therapy (decision taken by doctor prior to and independent of this noninterventional study) No ineligibility for rituximab Not Applicable (NA)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>